HIMS Shares Sink After FDA Vows "Swift Action" Against Copycat GLP-1 Drugs

Hims & Hers Health launched a cheaper copycat GLP-1 drug, initiating a price war in the weight loss drug market. The FDA responded swiftly, vowing action against companies marketing unapproved drugs claiming similarity to FDA-approved products. The FDA cannot guarantee the safety and efficacy of these unapproved medications. This move follows Novo Nordisk's previous termination of a partnership with Hims, citing illegal practices. Novo Nordisk faces competition from Eli Lilly's Zepbound, impacting its outlook. The FDA's statement, likely influenced by Novo, caused Hims' shares to plummet. Novo's shares, on the other hand, saw an increase. The situation reflects a "reset year" for GLP-1 pricing dynamics, as stated by Goldman's analyst. This could reflect a wider competition within the GLP-1 market. This action against Hims is a direct response to their aggressive market strategy.